Corvus Pharmaceuticals, Inc. (CRVS) › Cash & EquivalentsCorvus Pharmaceuticals, Inc. (CRVS) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2014: $12.52M2015: $4.11M2016: $5.05M2017: $45.11M2018: $39.20M2019: $5.15M2020: $16.45M2021: $63.46M2022: $13.16M2023: $12.62M2024: $8.74M2025: $4.58M$4.58M2014Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$4.58M-47.6%2024$8.74M-30.7%2023$12.62M-4.1%2022$13.16M-79.3%2021$63.46M+285.6%2020$16.45M+219.3%2019$5.15M-86.9%2018$39.20M-13.1%2017$45.11M+793.2%2016$5.05M+23.0%2015$4.11M-67.2%2014$12.52M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share